Literature DB >> 3080736

Current status of antibiotic treatment for Mycoplasma pneumoniae infections.

G H McCracken.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3080736     DOI: 10.1097/00006454-198601000-00054

Source DB:  PubMed          Journal:  Pediatr Infect Dis        ISSN: 0277-9730


× No keyword cloud information.
  10 in total

1.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

2.  Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  Monica Fonseca-Aten; Christine M Salvatore; Asunción Mejías; Ana M Ríos; Susana Chávez-Bueno; Kathy Katz; Ana M Gómez; George H McCracken; R Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Authors:  C Tagliabue; C Techasaensiri; J P Torres; K Katz; C Meek; T R Kannan; J J Coalson; S Esposito; N Principi; R Leff; J B Baseman; R D Hardy
Journal:  J Antimicrob Chemother       Date:  2011-07-25       Impact factor: 5.790

4.  Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.

Authors:  Ana María Ríos; Asunción Mejías; Susana Chávez-Bueno; Mónica Fonseca-Aten; Kathy Katz; Jeanine Hatfield; Ana María Gómez; Hasan S Jafri; George H McCracken; Octavio Ramilo; Robert Doug Hardy
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

5.  Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.

Authors:  C M Salvatore; C Techasaensiri; C Tagliabue; K Katz; N Leos; A M Gomez; G H McCracken; R D Hardy
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

6.  The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection.

Authors:  C Tagliabue; C M Salvatore; C Techasaensiri; A Mejias; J P Torres; K Katz; A M Gomez; S Esposito; N Principi; R D Hardy
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

7.  Mycoplasma pneumoniae pneumonia in children.

Authors:  You-Sook Youn; Kyung-Yil Lee
Journal:  Korean J Pediatr       Date:  2012-02-14

Review 8.  Antimicrobial therapy of community-acquired pneumonia.

Authors:  Thomas M File; Michael S Niederman
Journal:  Infect Dis Clin North Am       Date:  2004-12       Impact factor: 5.982

Review 9.  Infection with and Carriage of Mycoplasma pneumoniae in Children.

Authors:  Patrick M Meyer Sauteur; Wendy W J Unger; David Nadal; Christoph Berger; Cornelis Vink; Annemarie M C van Rossum
Journal:  Front Microbiol       Date:  2016-03-23       Impact factor: 5.640

10.  Are alternative antibiotics needed for antibiotic-nonresponsive Mycoplasma pneumoniae pneumonia?

Authors:  Eun-Ae Yang; Kyung-Yil Lee
Journal:  Clin Exp Pediatr       Date:  2020-02-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.